Actively Recruiting
Randomized Study of Two Doses of EXPD-101FXS7553 Versus Placebo to Treat COPD Over 52 Weeks
Led by Expedition Therapeutics, Inc · Updated on 2026-10-28
600
Participants Needed
35
Research Sites
1 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of two doses of the drug EXPD-101FXS7553 in adults with Chronic Obstructive Pulmonary Disease COPD. This Phase 2 trial aims to assess how well the drug works, its safety, how well participants tolerate it, and how the body processes it. Participants will be adults aged 40 to 85 years with a confirmed diagnosis of COPD and a history of chronic bronchitis and exacerbations. Participants will be randomly assigned to one of three groups one receiving Dose 1 of EXPD-101FXS7553, another receiving Dose 2 of the same drug, or a third group receiving a placebo. All treatments are given as oral tablets once daily for 52 weeks. The study is double-blinded, meaning neither participants nor researchers know who is receiving the drug or placebo during the treatment period. During the study, participants will attend regular visits for assessments including lung function tests, questionnaires about respiratory symptoms and quality of life, physical exams, vital signs, and electrocardiograms. Researchers will monitor for moderate and severe COPD exacerbations and any adverse events throughout the 52 weeks. Blood and sputum samples will be collected at various points to study drug levels and biological effects. The overall goal is to understand the drugs impact on COPD symptoms and safety over a year-long treatment period.
CONDITIONS
Brief Title
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Research Team
G
Geoffrey Gilmartin, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here